

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to:
www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	10
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	24
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	39
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	43
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	46
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Estonia (Eastern Europe)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.89	1.51	3.79
Year of IDU prevalence estimate	2004		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	54.3	72.1	89.9
Year of HIV prevalence among IDU estimate	2005		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	913 147 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	8000	13 500	34 500
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	4344	9733	31016

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other NSP indicators
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

NSP 2: Number of NSP sites

Data reported	23 Outreach sites 13 fixed sites		
Year of reported data	2009		
Reference	Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments	Assumed counts of all site are mutually exclusive. Total number of sites calculated.		
Final/Adjusted data (to be used as indicator numerator)	36		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	909 613 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	1.04	2.67	4.50

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	4088 new clients accessing NSPs		
Year of reported data	2008		
Reference	Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	4088		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	11.8	30.3	51.1

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	170 624 visits to the NSPs 89.6% NSPs reported data		
Year of reported data	2008		
Reference	Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments	For lower bound use data from sites reporting only For upper bound assume rate of client contact is constant across all sites and therefore reported figure represents 89.6% of total number of client contacts from all sites		
Final/Adjusted data (to be used as indicator numerator)	170 624 - 190 428		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	4.95	13.37	23.80

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	2 033 375 syringes distributed Additional 386 929 needles were distributed		
Year of reported data	2008		
Reference	Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	2 033 375		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	58.94	150.6	254.17

NSP: All documents reviewed

- Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.
- Aceijas, C., M. Hickman, et al. (2007). "Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia.[see comment]." *Addiction* 102(8): 1244-50.
- Alban, A. and J. Kutzin (2006). Scaling up treatment and care for HIV/AIDS and TB and accelerating prevention within the health system in the Baltic States (Estonia, Latvia, Lithuania): Economic, health financing and health system implications, World Health Organization: 47.
- Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.
- Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania.
- Drew, R., Donoghoe, M., Koppel, A., Laukamm-Josten, U., Politi, C., Rotberga, S., Sarang, A., & Stover, H (2008). Evaluation of Fighting HIV/AIDS in Estonia, WHO: 77.
- Drew, R., M. Donoghoe, et al. (2008). Evaluation of fighting HIV/AIDS in Estonia. WHO.
- EMCDDA (2007). The State of the Drugs Problem in Europe. Luxembourg: 100.
- Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.
- European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." *Statistical Bulletin* Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.
- European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." *Statistical Bulletin* 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.
- Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.
- Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.
- National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26May2009
- Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.
- Politi, C. and T. Torvand (2007). Financing HIV/AIDS and Tuberculosis interventions in Estonia. WHO Europe. Copenhagen
- Stover, H. (2008). Evaluation of National Responses to HIV/AIDS in Prison Settings in Estonia, UNODC: 75.
- Subata, E. (2007). Evaluation of Methadone Maintenance Therapy program in Estonia.
- Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.
- Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health
- Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tervise Arengu Instituut - National Institute for Health
- Uuskula, A., Abel, K., Rajaleid, K., Ruutel, K., Talu, A., Fisher, K. & Boborova, N. (2005). HIV and risk behaviour among injecting drug users in two cities (Tallinn, Kohtla-Järve) in Estonia. Tartu, National Institute for Health Development: 35.
- WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.
- WHO Europe and UNODC (2008). Evaluation of fighting HIV/AIDS in Estonia. Copenhagen, WHO,.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was agonist OST first available?	2001
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was MMT first available?	2001
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	World Health Organisation (2009). Global health ATLAS data.
When was BMT first available?	2003
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	
Comments	
Year	
Reference	
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	8 MMT sites 0 BMT sites		
Year of reported data	2008		
Reference	<p>Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health Development.</p> <p>Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.</p> <p>Politi, C. and T. Torvand (2007). Financing HIV/AIDS and Tuberculosis interventions in Estonia. WHO Europe. Copenhagen</p> <p>National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26May2009</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	8		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	0.23	0.59	1

OST 8: Number of sites providing MMT

Data reported	8 MMT sites		
Year of reported data	2008		
Reference	<p>Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health Development.</p> <p>Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.</p> <p>Politi, C. and T. Torvand (2007). Financing HIV/AIDS and Tuberculosis interventions in Estonia. WHO Europe. Copenhagen</p> <p>National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26May2009</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	8		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	0.23	0.59	1

OST 9: Number of sites providing BMT

Data reported	BMT available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	909 613 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	1044 clients in MMT - [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	1044		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	3.03	7.46	13.05

OST 12: Number of all clients in MMT at a single point in time

Data reported	1044 clients in MMT [No information on whether number of clients in MMT at single point in time (i.e. Census date) or total number of clients receiving MMT over a period of time]		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed count equals enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	1044		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	3.03	7.46	13.05

OST 13: Number of all clients in BMT at a single point in time

Data reported	BMT available but number of clients not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	1044 clients in MMT - [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed count equal to total number of clients enrolled in OST throughout 2007		
Final/Adjusted data (to be used as indicator numerator)	1044		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	3.03	7.46	13.05

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	1044 clients in MMT [No information on whether number of clients in MMT at single point in time (i.e. Census date) or total number of clients receiving MMT over a period of time]		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed count equals total number of clients enrolled in MMT throughout 2007		
Final/Adjusted data (to be used as indicator numerator)	1044		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	3.03	7.46	13.05

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT available but number of clients not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High

OST: All documents reviewed

Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.

Alban, A. and J. Kutzin (2006). Scaling up treatment and care for HIV/AIDS and TB and accelerating prevention within the health system in the Baltic States (Estonia, Latvia, Lithuania): Economic, health financing and health system implications, World Health Organization: 47.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania.

Drew, R., Donoghoe, M, Koppel, A, Laukamm-Josten, U, Politi, C, Rotberga, S, Sarang, A, & Stover, H (2008). Evaluation of Fighting HIV/AIDS in Estonia, WHO: 77.

Drew, R., M. Donoghoe, et al. (2008). Evaluation of fighting HIV/AIDS in Estonia. WHO.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." Statistical Bulletin Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.

Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.

National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26May2009

Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.

Politi, C. and T. Torvand (2007). Financing HIV/AIDS and Tuberculosis interventions in Estonia. WHO Europe. Copenhagen

Reitox National Focal Point (2008). Estonia - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

Stover, H. (2008). Evaluation of National Responses to HIV/AIDS in Prison Settings in Estonia, UNODC: 75.

Subata, E. (2007). Evaluation of Methadone Maintenance Therapy program in Estonia.

Trummal, A. (Chief analyst), Department of Surveillance and Evaluation, National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Tallinn, Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.

Trummal, A., L. Löhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health

Trummal, A., L. Löhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tervise Arengu Instituut - National Institute for Health

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

WHO Europe and UNODC (2008). Evaluation of fighting HIV/AIDS in Estonia. Copenhagen, WHO,.

3. Other drug treatment (ODT)

ODT 1 - Detoxification

ODT 1.1: Number of sites providing detoxification

Is detoxification available?	Yes		
Number of sites - data reported	Detox available in prisons [No information on community programs]		
Year of reported data	2006		
Reference	Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2006		
Reference	Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2006		
Reference	Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?	Yes		
Number of sites - data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Estonia - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Estonia - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 2.3: Number of all clients in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Estonia - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	915 772 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2006		
Reference	<p>Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.</p> <p>Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2006		
Reference	<p>Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.</p> <p>Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2006		
Reference	<p>Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.</p> <p>Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	6 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	6		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	0.17	0.44	0.75

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.

Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.

Reitox National Focal Point (2008). Estonia - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health

WHO Europe and UNODC (2008). Evaluation of fighting HIV/AIDS in Estonia. Copenhagen, WHO,.

4. HIV testing and counselling (T&C)

T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2008
Reference	Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health Development. European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported	2 treatment centres provided testing targeting IDUs		
Year of reported data	2006		
Reference	Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	2		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High
	0.06	0.14	0.25

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	6 anonymous HIV cabinets 2 treatment centres provided testing targeting IDUs.		
Year of reported data	2006		
Reference	Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.		
Adjustments	Assume the site counts are mutually exclusive		
Final/Adjusted data (to be used as indicator numerator)	8		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	0.23	0.57	1

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2007
Reference	UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.
Data reported for both male and female IDUs	62% IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	62%
Data reported for male IDUs	63% Male IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	63%
Data reported for female IDUs	60% Female IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	60%

T&C: All documents reviewed

Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Drew, R., Donoghoe, M, Koppel, A, Laukamm-Josten, U, Politi, C, Rotberga, S, Sarang, A, & Stover, H (2008). Evaluation of Fighting HIV/AIDS in Estonia, WHO: 77.

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.

Subata, E. (2007). Evaluation of Methadone Maintenance Therapy program in Estonia.

Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

WHO Europe and UNODC (2008). Evaluation of fighting HIV/AIDS in Estonia. Copenhagen, WHO,.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	4 sites offering free ART to PLWHA without health insurance		
Year of reported data	2006		
Reference	Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.		
Adjustments	Assumed no other ART sites		
Final/Adjusted data (to be used as indicator numerator)	4		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	917 390 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	34 500
HIV among IDU prevalence estimate (%)	Low	Mid	High
	54.30	72.10	89.90
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	4344	10094	31016
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	0.12	0.29	0.50
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	0.13	0.40	0.92

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	13 active IDUs are on ART. These 13 IDUs represent 8% of all IDUs on ART		
Year of reported data	2005		
Reference	European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.		
Adjustments	Calculated the total number of IDUs on ART		
Final/Adjusted data (to be used as indicator numerator)	163		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	918 004 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	14 000	35 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	54.30	72.10	89.90
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	4344	10094	31 465
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	0.52	1.61	3.75

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	No restrictions
Year of reported data	2007
Reference	Bollerup, A. R., M. C. Donoghoe, et al. (2007). Access to HAART for injecting drug users in the WHO European Region 2002-2005, POSTER1 (930). 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association,.

ARV: All documents reviewed

- Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.
- Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.
- Bollerup, A. R., M. C. Donoghoe, et al. (2007). Access to HAART for injecting drug users in the WHO European Region 2002-2005, POSTER1 (930). 18th International Conference on the Reduction of Drug Related Harm,. Warsaw, Poland, International Harm Reduction Association,.
- Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.
- Donoghoe, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004." *International Journal of Drug Policy* 18(4): 271-80.
- Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania.
- Drew, R., Donoghoe, M, Koppel, A, Laukamm-Josten, U, Politi, C, Rotberga, S, Sarang, A, & Stover, H (2008). Evaluation of Fighting HIV/AIDS in Estonia, WHO: 77.
- Drew, R., M. Donoghoe, et al. (2008). Evaluation of fighting HIV/AIDS in Estonia. WHO.
- European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.
- Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.
- Subata, E. (2007). Evaluation of Methadone Maintenance Therapy program in Estonia.
- WHO Europe and UNODC (2008). Evaluation of fighting HIV/AIDS in Estonia. Copenhagen, WHO,.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	
Year	2008
Reference	See references for other Condom indicators

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2008		
Reference	National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26May2009		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	NK	NK	NK

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	754 874 condoms distributed		
Year of reported data	2008		
Reference	National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26May2009		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	754 874		
IDU prevalence estimate (%)	Low	Mid	High
	0.89	1.51	3.79
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 147 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	8000	13 500	34 500
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	21.88	55.92	94.36

Condoms: All documents reviewed

Abel-Ollo, K., Talu, A., Vals, K., Vorobjov, S., Paimre, M., Ahven, A., Neuman, A. and Denissov, G. (2007). Report on the drug situation in Estonia 2007. Tallinn, National Institute for Health Development: 61.

Alban, A. and J. Kutzin (2006). Scaling up treatment and care for HIV/AIDS and TB and accelerating prevention within the health system in the Baltic States (Estonia, Latvia, Lithuania): Economic, health financing and health system implications, World Health Organization: 47.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.

Family Health International (2007). Baltic Sea HIV/AIDS Regional Initiative. Arlington VA: 65.

Kalikov, J. and A. Wasson-Simon (2004). HIV and AIDS in Estonia: first we got the heroine epidemic, then we got one of the worst HIV epidemic in Eastern Europe. Country report, Integration Projects.

National Institute for Health Development. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Estonia". Estonia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26May2009

Oole, K., Talu, A., Vals, K., Paimre, M., Ahven, A., Neuman, A., Denissov, G. and Abel, K. (2006). ESTONIA: New developments, trends and in-depth information on selected issues. Tallinn, Estonian Drug Monitoring Centre: 75.

Politi, C. and T. Torvand (2007). Financing HIV/AIDS and Tuberculosis interventions in Estonia. WHO Europe. Copenhagen

Subata, E. (2007). Evaluation of Methadone Maintenance Therapy program in Estonia.

Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tallinn, Tervise Arengu Instituut, National Institute for Health

Trummal, A., L. Lõhmus, et al. (2008). Fighting HIV in Estonia in 2006 and 2007. Tervise Arengu Instituut - National Institute for Health